

It is illegal to post this copyrighted PDF on any website.

Evaluation of Cardiometabolic Risk in a Large Psychiatric Cohort and Comparison With a Population-Based Sample in Switzerland

Céline Dubath, PharmD^a; Aurélie Delacrétaiz, PhD^{a,e}; Anaïs Glatard, PhD^a; Peter Vollenweider, MD^b; Martin Preisig, MD, MPH^c; Hélène Richard-Lepouriel, MD^d; Roland Hasler, PhD^d; Franziska Gamma, MD, MSc^e; Alessandra Solida, MD^f; Jacques Thonney, MD^f; Sylfa Fassassi, MD^f; Armin von Gunten, MPhil, MD^g; Philippe Conus, MD^f; and Chin B. Eap, PhD^{a,h,*}

ABSTRACT

Background: Psychiatric patients are known to be at high risk of developing cardiovascular diseases (CVDs), leading to an increased mortality rate.

Objective: To assess the CVD risk (presence of metabolic syndrome [MetS] and calculated 10-year CVD risk) in a Swiss psychiatric cohort taking weight gain–inducing psychotropic drugs, compare the findings to a Swiss population-based cohort, and evaluate the prevalence of participants treated for metabolic disruptions in both cohorts.

Methods: Data for 1,216 psychiatric patients (of whom 634 were aged 35–75 years) were obtained between 2007 and 2017 from a study with metabolic parameters monitored during psychotropic treatment and between 2003 and 2006 for 6,733 participants from the population-based CoLausPsyCoLaus study.

Results: MetS as defined by the International Diabetes Federation (IDF) was identified in 33% of the psychiatric participants and 24.7% of the population-based subjects. Specifically, prevalence per the IDF definition was more than 3 times higher in the psychiatric cohort among women aged 35 to 49 years (25.6% vs 8.0%; $P < 10^{-4}$). The psychiatric and population-based cohorts, respectively, had comparable predicted CVD risk (10-year risk of CVD event $> 20\%$: 0% vs 0.1% in women and 0.3% vs 1.8% [$P = .01$] in men; 10-year risk of CVD death $> 5\%$: 8.5% vs 8.4% [$P = .58$] in women and 13.4% vs 16.6% [$P = .42$] in men). No difference was observed among the proportion of participants with MetS treated for metabolic disturbances in the two cohorts, with the exception of women aged 35–49 years, for whom those in the psychiatric cohort were half as likely to receive treatment compared to participants in CoLausPsyCoLaus (17.8% vs 38.8% per the IDF definition; $P = .0004$).

Conclusions: These findings emphasize the concern that psychiatric patients present an altered metabolic profile and that they do not receive adequate treatment for metabolic disruptions. Presence of metabolic disturbances should be routinely assessed, and adequate follow-up is needed to intervene early after illness onset.

J Clin Psychiatry 2020;81(3):19m12796

To cite: Dubath C, Delacrétaiz A, Glatard A, et al. Evaluation of cardiometabolic risk in a large psychiatric cohort and comparison with a population-based sample in Switzerland. *J Clin Psychiatry*. 2020;81(3):19m12796.

To share: <https://doi.org/10.4088/JCP.19m12796>

© Copyright 2020 Physicians Postgraduate Press, Inc.

^aUnit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland

^bDepartment of Medicine, Internal Medicine, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland

^cCenter of Psychiatric Epidemiology and Psychopathology, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland

^dDepartment of Mental Health and Psychiatry, University Hospital of Geneva, Geneva, Switzerland

^eLes Toises Psychiatry and Psychotherapy Center, Lausanne, Switzerland

^fService of General Psychiatry, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland

^gService of Old Age Psychiatry, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland

^hSchool of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland

*Corresponding author: Chin B. Eap, PhD, Hôpital de Cery, 1008 Prilly—Lausanne, Switzerland (Chin.Eap@chuv.ch).

People with mental disorders have a high morbidity and mortality rate with a reduced life expectancy compared to the general population.¹ Studies diverge on the estimated mortality gap; however, a recent review¹ of 22 studies reported a median of 10 years' reduced life expectancy, with evidence that this difference is increasing over time. Although suicides are one main concern in this population, natural causes account for approximately two-thirds of these premature deaths. Indeed, people with mental disorders tend to have adverse health behaviors, including tobacco and substance use, physical inactivity, and unhealthy diets. In addition, they often have poor access to appropriate care and develop chronic diseases, mainly cardiovascular diseases (CVDs). Furthermore, patients treated with psychotropic drugs, including atypical and conventional antipsychotics, mood stabilizers (eg, valproate and lithium), and antidepressants (eg, mirtazapine), are exposed to metabolic side effects, increasing their risk of developing CVD.^{2–5} Unfortunately, preventive strategies remain a low priority for psychiatric patients among clinicians, and a large majority of psychiatric patients are not treated for their metabolic conditions.^{6–9}

In the general population, CVD is among the leading causes of death worldwide.¹⁰ Many scoring systems have been developed to evaluate CVD risk. The Framingham Risk Score (FRS), which gives an estimation of the 10-year risk of a CVD event, is widely used^{11–13} but does not adequately predict CVD risk when applied to populations with lower CVD incidence. In Europe, the Systematic Coronary Risk Estimation (SCORE),¹⁴ proposed by the European Society of Cardiology, is preferred as it is based on European epidemiologic studies. This score provides an estimate of the 10-year risk of fatal CVD and is recommended to help clinicians evaluate their patients' risks and make decisions on which treatment strategy

Clinical Points

- Cardiometabolic health is a great concern in psychiatric patients, especially those initiating a psychotropic treatment known to induce metabolic side effects.
- Prevalence of metabolic syndrome is much higher in psychiatric patients than in the general population, with marked differences highlighted already in young patients.
- Careful monitoring of metabolic profile is warranted in psychiatric patients, as is supporting these patients in engaging in weight control strategies.

to adopt.¹⁵ These two risk scores have been calibrated for the Swiss population, using national CVD death rate and an estimation of the number of events based on the Vaud-Fribourg MONICA study.¹⁶ Validation of these calibrated scores in the CoLaus study in the Lausanne area has shown them to be strong predictors of CVD events¹⁷ and CVD deaths,¹⁸ respectively.

CVD risk can also be estimated by assessing for the presence of metabolic syndrome (MetS).¹⁹ MetS is defined by the combined presence of metabolic disorders such as central obesity (ie, according to high waist circumference), raised triglycerides, reduced high-density lipoprotein (HDL) cholesterol, raised blood pressure, and/or raised fasting glycemia. Although the precise definition has been a matter of debate, this clustering is associated with the risk of developing CVD and type 2 diabetes.^{20,21} MetS is more predictive of CVD events than the sum of isolated risk factors and is thus widely used as an early diagnostic tool to help decision making regarding treatment interventions.^{22,23}

The psychiatric population is well known to be at higher risk of CVD compared to the general population; however, these differences are poorly understood and not well characterized. The first aim of the present study was to compare the prevalence of MetS between a Swiss cohort treated with weight-gain-inducing psychotropic drugs and a population-based sample. In addition to the presence of MetS, the CVD risk was further quantified using the FRS and SCORE, calibrated for the Swiss population. Additionally, this study sought to evaluate the proportion of patients receiving treatments for their metabolic disturbances (antihypertensive, lipid-lowering, or antidiabetic drug prescription) and assess whether it differed from that in the population-based sample.

METHODS

Study Design

An observational prospective study has been ongoing since 2007 in the Department of Psychiatry of the Lausanne University Hospital, in the Department of Psychiatry of the Geneva University Hospital, and in a private mental health care center (Les Toises; Lausanne, Switzerland), focusing on side effects of psychotropic treatments, approved by the Ethic Committee of the Canton of Vaud (CER-VD). This

large study benefits from data and blood samples collected from 2007 to 2017 during routine clinical visits of patients who gave their informed consent. Because of the non-interventional post hoc analysis study design, the Ethic Committee approved the use of clinical data of followed-up patients from 2007 to end of 2015 in the Department of Psychiatry of the Lausanne University Hospital without informed consent.

Only cross-sectional data were used in the present research. The inclusion criterion for the study was the prescription of a psychotropic treatment known to display metabolic side effects, and both inpatients and outpatients not differentiating for early psychosis and chronically ill patients were considered (see Supplementary Appendix 1 for more information). Included patients, who constitute psychiatric sample 1, are noted in Supplementary Figure 1. The presence of MetS was assessed using two of the most commonly used definitions: the International Diabetes Federation (IDF) and the adapted National Cholesterol Education Program's Adult Treatment Panel III (ATP) definitions (Supplementary Table 3).^{24,25} The CVD risk was further quantified using the FRS and SCORE, calibrated for the Swiss population.^{17,18}

To compare our psychiatric sample with the general population, we used data from the CoLaus|PsyCoLaus study. This study is population-based and included participants aged 35 to 75 years living in Lausanne, Switzerland. Briefly, the CoLaus|PsyCoLaus study assessed cardiovascular risk factors and diseases and collected various genetic variants and biomarkers. The baseline recruitment and medical assessment of the CoLaus|PsyCoLaus sample, which was completed between 2003 and 2006, has already been described in detail.²⁶ As our psychiatric sample included patients aged 12 to 96 years, we selected a subsample aged 35 to 75 years (psychiatric sample 2) for comparison with the population-based sample (see Supplementary Figure 1).

Statistical Analysis

Descriptive statistics including frequencies and percentages for the categorical variables and median and interquartile range (IQR) for the continuous variables were calculated. Associations of CVD risk scores and MetS with clinical characteristics (age, sex, smoking status, illness duration, diagnosis, and psychotropic medication) were tested using linear and logistic regression models, respectively (see Supplementary Appendix 1 for more information).

Differences between men and women in the psychiatric sample were tested for significance using Pearson χ^2 tests for categorical variables and Wilcoxon Mann-Whitney rank sum tests for continuous variables. For the comparison with the population-based sample, weighted *t* tests were conducted to account for age difference. The analyses were conducted for both men and women separately and were also stratified by age.

Statistical significance was determined by a *P* value $\leq .05$. Statistical analyses were performed using Stata 14

It is illegal to post this copyrighted PDF on any website.

Table 1. Demographic and Clinical Characteristics, including Prevalence of Metabolic Syndrome and Quantification of the 10-Year Cardiovascular Disease Risk, in Psychiatric Sample 1 (aged 12–96 years)^a

Characteristic	Women	Men	Total	P Value ^b
Sample size, n (%)	626 (51.5)	590 (48.5)	1,216	
Age, median (IQR), y	45 (32–63)	35 (26–51)	41 (28–56)	<10⁻⁴
Smoker, n (%)	271 (43.3)	377 (63.9)	648 (53.3)	<10⁻⁴
Diagnosis, ^c n (%)				
Psychotic disorders (F20–F24; F28–F29)	113 (18.1)	194 (32.9)	307 (25.3)	<10⁻⁴
Schizoaffective disorders (F25)	40 (6.4)	34 (5.8)	74 (6.1)	.65
Bipolar disorders (F30–F31)	85 (13.6)	71 (12.0)	156 (12.8)	.42
Depressive disorders (F32–F33)	115 (18.4)	49 (8.3)	164 (13.5)	<10⁻⁴
Other	79 (12.6)	51 (8.6)	130 (10.7)	.03
Not available	194 (31.0)	191 (32.4)	385 (31.7)	.60
Psychotropic medication, ^d n (%)				
Low risk	112 (17.9)	131 (22.2)	243 (20.0)	.06
Medium risk	386 (61.7)	328 (55.6)	714 (58.7)	.03
High risk	128 (20.4)	131 (22.2)	259 (21.3)	.46
BMI, median (IQR), kg/m ²	24 (21–29)	25 (22–28)	25 (21–28)	.13
Waist circumference, median (IQR), cm	88 (78–98)	93 (84–104)	90 (81–101)	<10⁻⁴
A. Central obesity prevalence (IDF), n (%) ^{e,f}	434 (69.4)	275 (46.8)	709 (58.5)	<10⁻⁴
B. Central obesity prevalence (ATP), n (%) ^{e,f}	315 (50.6)	170 (29.0)	485 (40.1)	<10⁻⁴
Systolic blood pressure, median (IQR), mm Hg	120 (110–130)	124 (115–136)	120 (110–132)	<10⁻⁴
Diastolic blood pressure, median (IQR), mm Hg	76 (69–85)	80 (70–86)	78 (70–85)	10⁻⁴
C. Hypertension prevalence, n (%) ^e	153 (24.4)	172 (29.2)	325 (26.7)	.06
Plasma cholesterol				
Total, median (IQR), mmol/L	5 (4.3–5.7)	4.7 (3.9–5.5)	4.8 (4.1–5.6)	<10⁻⁴
LDL, median (IQR), mmol/L	2.9 (2.2–3.5)	2.7 (2.1–3.4)	2.8 (2.1–3.5)	.004
HDL, median (IQR), mmol/L	1.5 (1.2–1.7)	1.2 (1.0–1.5)	1.3 (1.1–1.6)	<10⁻⁴
D. HDL hypocholesterolemia prevalence, n (%) ^{e,f}	209 (33.4)	194 (32.9)	403 (33.2)	.84
Plasma triglycerides, median (IQR), mmol/L	1.1 (0.8–1.6)	1.2 (0.9–1.9)	1.2 (0.9–1.7)	.0004
E. Hypertriglyceridemia prevalence, n (%) ^{e,f}	162 (26.0)	197 (33.4)	359 (29.6)	.004
Fasting plasma glucose, median (IQR), mmol/L	5.1 (4.7–5.5)	5.1 (4.7–5.6)	5.1 (4.7–5.5)	.09
F. Raised fasting plasma glucose prevalence, n (%) ^{e,f}	156 (25.2)	153 (26.0)	309 (25.6)	.73
MetS (IDF) prevalence, n (%)	164 (26.3)	138 (23.4)	302 (24.9)	.24
MetS (ATP) prevalence, n (%)	147 (23.7)	135 (22.9)	282 (23.3)	.76

^aClinical characteristics of patients were measured at their first visit, which was at baseline for 48% of the sample, month 1 for 21%, month 2 for 3%, month 3 for 19%, and month 5 or later for the rest of the sample.

^bStatistical significance for differences between men and women was tested using the Wilcoxon Mann-Whitney test for continuous variables and Pearson χ^2 test for categorical variables. P values in bold are significant ($\leq .05$).

^cDiagnoses were based on ICD-10 classification. Organic disorders, anxiety, personality disorder, and mental retardation were classified together as “other.”

^dPsychotropic medications were classified according to the risk of weight gain as follows: low risk: haloperidol, pipamperone, flupentixol, asenapine, amisulpride, aripiprazole, and lurasidone; medium risk: zuclopenthixol, levomepromazine, paliperidone, risperidone, quetiapine, lithium, and mirtazapine; high risk: valproate, olanzapine, and clozapine.

^eThresholds for metabolic abnormalities: A. waist circumference: men, ≥ 94 cm; women, ≥ 80 cm and/or BMI > 30 kg/m²; B. waist circumference: men, ≥ 102 cm; women, ≥ 88 cm; C. blood pressure $\geq 130/85$ mm Hg or treatment for hypertension; D. HDL hypocholesterolemia: men, ≤ 1.03 mmol/L; women, ≤ 1.29 mmol/L or lipid-lowering treatment; E. triglycerides ≥ 1.7 mmol/L or lipid-lowering treatment; F. glucose ≥ 5.6 mmol/L or type 2 diabetes treatment.

^fThe total n value used in the calculations of percentages for the following variables differs from the values listed for overall sample size due to missing data: A. central obesity (IDF): n = 1,212; B. central obesity (ATP): n = 1,210; D. HDL hypocholesterolemia: n = 1,204; E. hypocholesterolemia: n = 1,214; F. increased fasting plasma glucose: n = 1,204; MetS (IDF): n = 1,212; MetS (ATP): n = 1,210.

Abbreviations: ATP = National Cholesterol Education Program Adult Treatment Panel III, BMI = body mass index, HDL = high-density lipoprotein, IDF = International Diabetes Federation, IQR = interquartile range, LDL = low-density lipoprotein, MetS = metabolic syndrome.

(StataCorp; College Station, Texas) and RStudio version 0.99.879 (RStudio, Inc; Boston, Massachusetts).

RESULTS

Table 1 displays demographic and clinical characteristics of psychiatric sample 1, which includes 1,216 patients. Male patients represented 48.5% of the sample and were significantly younger than female patients. Most of the measured variables showed significant differences between men and women, justifying the stratification by sex. For instance, 43.3% of women and 63.9% of men ($P < 10^{-4}$)

were smokers. The most commonly prescribed medications were those classified as having a medium potential to induce weight gain; these medications were prescribed to 58.7% of participants.

Central obesity represented the most prevalent metabolic risk factor, as it was present in 69.4% and 46.8% of women and men, respectively, per the IDF definition and in 50.6% and 29.0%, respectively, per the ATP definition ($P < 10^{-4}$ for both). Median blood pressure was 120/78 mm Hg (IQR, 110–132/70–85), with men presenting with slightly higher values than women ($P < 10^{-4}$), although only a trend was found when comparing hypertension prevalence

Table 2. Clinical Variables and Prevalence of Metabolic Syndrome in Psychiatric Sample 2 and Comparison With the Population-Based Sample (aged 35–75 years)

Variable	Women-Psy	Women-Gpop	P Value ^a	Men-Psy	Men-Gpop	P Value ^a	Total-Psy	Total-Gpop
Sample size, n (%)	351 (55.4)	3,544 (52.6)		283 (44.6)	3,189 (47.4)		634	6,733
Age, median (IQR), y	49 (43–61)	52 (44–62)	.02	49 (41–58)	51 (43–61)	.002	49 (42–60)	52 (44–61)
Smoker, n (%)	171 (48.7)	880 (24.8)	<10⁻⁴	171 (60.4)	932 (29.3)	<10⁻⁴	342 (53.9)	1,812 (26.9)
BMI, median (IQR), kg/m ²	25 (22–29)	24 (22–28)	.004	26 (23–29)	26 (24–29)	.48	26 (22–29)	25 (23–28)
Waist circumference, median (IQR), cm	90 (81–100)	81 (74–91)	<10⁻⁴	98 (90–107)	95 (88–102)	.0006	94 (85–105)	89 (79–98)
A. Central obesity prevalence (IDF), n (%) ^b	265 (75.7)	1,974 (55.7)	<10⁻⁴	166 (59.1)	1,734 (54.4)	.84	431 (68.3)	3,708 (55.1)
B. Central obesity prevalence (ATP), n (%) ^b	199 (56.9)	1,152 (32.5)	<10⁻⁴	112 (39.9)	823 (25.8)	.0006	311 (49.3)	1,975 (29.3)
Systolic blood pressure, median (IQR), mm Hg	120 (110–130)	122 (112–135)	.17	125 (116–138)	130 (120–142)	<10⁻⁴	123 (112–135)	126 (116–139)
Diastolic blood pressure, median (IQR), mm Hg	80 (70–88)	77 (70–84)	.03	80 (75–90)	81 (74–88)	.75	80 (71–89)	79 (72–86)
C. Hypertension prevalence, n (%) ^b	97 (27.6)	1,069 (30.2)	.79	106 (37.5)	1,354 (42.5)	.03	203 (32.0)	2,423 (36.0)
Treated for hypertension, n (%) ^c	44 (45.4)	660 (61.7)	.07	42 (39.6)	689 (50.9)	.61	86 (42.4)	1,349 (55.7)
Total plasma cholesterol, median (IQR), mmol/L	5.2 (4.5–6)	5.5 (4.9–6.3)	<10⁻⁴	4.9 (4.2–5.7)	5.5 (4.8–6.2)	<10⁻⁴	5.1 (4.4–5.9)	5.5 (4.9–6.2)
Plasma HDL cholesterol, median (IQR), mmol/L	1.5 (1.2–1.8)	1.8 (1.5–2.1)	<10⁻⁴	1.2 (1–1.5)	1.4 (1.2–1.6)	<10⁻⁴	1.4 (1.1–1.7)	1.6 (1.3–1.9)
D. Hypocholesterolemia prevalence, n (%) ^b	114 (32.6)	308 (8.7)	<10⁻⁴	95 (33.6)	394 (12.4)	<10⁻⁴	209 (33.0)	702 (10.4)
Plasma triglycerides, median (IQR), mmol/L	1.2 (0.9–1.7)	1 (0.7–1.4)	<10⁻⁴	1.4 (1–2.1)	1.3 (0.9–1.9)	.81	1.3 (0.9–1.9)	1.1 (0.8–1.6)
E. Hypertriglyceridemia prevalence, n (%) ^b	105 (29.9)	576 (16.3)	<10⁻⁴	121 (42.9)	1,096 (34.4)	.02	226 (35.7)	1,672 (24.9)
Treated for hypertriglyceridemia, n (%) ^c	24 (22.9)	26 (4.8)	<10⁻⁴	25 (20.7)	23 (2.3)	<10⁻⁴	49 (21.7)	49 (3.2)
Fasting plasma glucose, median (IQR), mmol/L	5.2 (4.7–5.7)	5.2 (4.9–5.6)	.047	5.3 (4.9–5.9)	5.5 (5.2–6)	.30	5.2 (4.8–5.8)	5.4 (5–5.8)
F. Raised fasting plasma glucose prevalence, n (%) ^b	109 (31.2)	931 (26.3)	.0005	104 (36.9)	1,596 (50.1)	<10⁻⁴	213 (33.8)	2,527 (37.5)
Diabetes prevalence, ^d n (%)	31 (8.8)	142 (4.0)	.002	31 (11.0)	294 (9.2)	.36	62 (9.8)	436 (6.5)
Treated for diabetes, n (%) ^c	17 (54.8)	92 (64.8)	.46	17 (54.8)	183 (62.2)	.64	34 (54.8)	275 (63.1)
MetS (IDF) prevalence, n (%)	110 (31.6)	636 (18.0)	<10⁻⁴	98 (34.8)	1,025 (32.1)	.97	207 (33.0)	1,661 (24.7)
Treated, ^e n (%) ^c	46 (42.6)	370 (58.5)	.21	39 (39.4)	472 (46.1)	.96	85 (41.1)	842 (50.9)
MetS (ATP) prevalence, n (%)	97 (27.9)	530 (15.0)	<10⁻⁴	93 (33.0)	829 (26.0)	.04	190 (30.2)	1,359 (20.2)
Treated, ^e n (%) ^c	44 (45.8)	323 (61.6)	.07	36 (40.9)	413 (49.9)	.99	80 (43.5)	736 (54.5)

^aStatistical significance for difference between the psychiatric and population-based samples was tested using a weighted statistic according to participants' age (2-sample weighted *t* test), except for the age distribution, for which a standard *t* test was used. *P* values in bold are significant ($\leq .05$).

^bThresholds for metabolic abnormalities: A. waist circumference: men, ≥ 94 cm; women, ≥ 80 cm and/or BMI > 30 kg/m²; B. waist circumference: men, ≥ 102 cm; women, ≥ 88 cm; C. blood pressure $\geq 130/85$ mm Hg or treatment for hypertension; D. HDL cholesterol: men, ≤ 1.03 mmol/L; women, ≤ 1.29 mmol/L or lipid-lowering treatment; E. triglycerides ≥ 1.7 mmol/L or lipid-lowering treatment; F. glucose ≥ 5.6 mmol/L or type 2 diabetes treatment.

^cPercentages are calculated as number of treated patients over number of patients with disease.

^dDiabetes was defined as glucose > 7 mmol/L or type 2 diabetes treatment.

^eTreated: prevalence of any CVD medication intervention among MetS participants (ie, antihypertensive, lipid-lowering, or antidiabetic drug prescription).

Abbreviations: ATP = National Cholesterol Education Program Adult Treatment Panel III, BMI = body mass index, CVD = cardiovascular disease,

Gpop = population-based sample, IDF = International Diabetes Federation, IQR = interquartile range, MetS = metabolic syndrome, Psy = psychiatric sample.

(29.2% vs 24.4%, respectively; $P = .06$). Concerning lipid traits, women showed higher levels of total cholesterol and HDL cholesterol and lower levels of triglycerides than men (median: total cholesterol = 5.0 mmol/L, HDL cholesterol = 1.5 mmol/L and triglycerides = 1.1 mmol/L vs total cholesterol = 4.7 mmol/L, HDL cholesterol = 1.2 mmol/L and triglycerides = 1.2 mmol/L, respectively; all $P \leq .0004$). About one-third of participants reached cutoff values for lipid disturbances: 33.2% had HDL hypocholesterolemia overall, and 26.0% and 33.4% of women and men, respectively, had hypertriglyceridemia ($P = .004$). Elevated fasting plasma glucose level was less prevalent (25.6%) than other risk factors, with a median value of 5.1 mmol/L (IQR, 4.7–5.5). Combining these individual risk factors, 24.9%

and 23.3% of participants (with no significant difference between men and women) met IDF and ATP definitions for MetS, respectively.

Per linear regression models adjusted for age, sex, smoking status, and body mass index (BMI), no association was observed between psychiatric diagnosis and CVD risk scores or between psychotropic medication and CVD risk scores. Age, illness duration, and smoking status showed significant association with MetS ($P < .05$), while sex, psychiatric diagnosis, and psychotropic medication showed no significant association. Indeed, according to IDF criteria, an increase of 10 years of age was associated with a 1.35-fold (95% CI, 1.27–1.48, $P < 10^{-4}$) greater odds of MetS, while chronic compared with early psychosis patients had an

It is illegal to post this copyrighted PDF on any website

Table 3. Quantification of the 10-Year Cardiovascular Disease Risk in the Psychiatric Sample 2 and Comparison With the Population-Based Sample (aged 35–75 years)^a

Variable	Women			Men			Total-Psy	Total-Gpop
	Psy	Gpop	P Value ^b	Psy	Gpop	P Value ^b		
SCORE, median (IQR), %	0.28 (0.12–1.32)	0.36 (0.12–1.34)	.54	0.85 (0.38–2.25)	1.04 (0.43–3.45)	0.14	0.52 (0.19–1.75)	0.63 (0.23–2.18)
Prevalence, n (%)								
High risk ($\geq 5\%$)	30 (8.5)	296 (8.4)	.58	38 (13.4)	528 (16.6)	.42	68 (10.7)	824 (12.3)
Intermediate risk ($2.5 \geq \text{risk} < 5\%$)	26 (7.4)	240 (6.8)	.50	27 (9.5)	476 (15.0)	.18	53 (8.4)	716 (10.7)
Low risk ($1.5 \geq \text{risk} < 2.4\%$)	21 (6.0)	269 (7.6)	.50	34 (12.0)	316 (10.0)	.02	55 (8.7)	585 (8.7)
Very low risk ($< 1.5\%$)	274 (78.1)	2723 (77.2)	.24	184 (65.0)	1,856 (58.4)	.83	458 (72.2)	4,579 (68.3)
FRS, median (IQR), %	0.40 (0.18–0.81)	0.41 (0.17–0.93)	.57	1.72 (0.95–3.39)	2.54 (1.20–5.03)	$< 10^{-4}$	0.82 (0.33–1.88)	1.00 (0.36–2.72)
Prevalence, n (%)								
High risk ($> 20\%$)	0	2 (0.1)	...	1 (0.3)	58 (1.8)	.01	1 (0.1)	60 (0.9)
Intermediate risk ($10 < \text{risk} \leq 20\%$)	0	5 (0.1)	...	7 (2.5)	192 (6.0)	.0002	7 (1.1)	197 (2.9)
Low risk ($6 < \text{risk} \leq 10\%$)	3 (0.8)	14 (0.4)	.66	19 (6.7)	376 (11.8)	.0006	22 (3.5)	390 (5.8)
Very low risk ($\leq 6\%$)	348 (99.1)	3521 (99.4)	.95	256 (90.5)	2,559 (80.4)	$< 10^{-4}$	604 (95.3)	6,080 (90.4)

^aTotal n values: SCORE: women: Psy n = 351, Gpop n = 3,528; men: Psy n = 283, Gpop n = 3,176; Total-Psy n = 634; Total-Gpop n = 6,704. FRS: women: Psy n = 351, Gpop n = 3,542; men: Psy n = 283, Gpop n = 3,185; Total-Psy n = 634; Total-Gpop n = 6,727.

^bStatistical significance for difference between the psychiatric and population-based samples was tested using a weighted statistic according to participants' age (2-sample weighted t test). P values in bold are significant ($\leq .05$).

Abbreviations: FRS = Framingham Risk Score, Gpop = population-based sample; Psy = psychiatric sample, SCORE = Systematic Coronary Risk Estimation.

increased risk of MetS, with an odds ratio of 2.3 (95% CI, 1.4–3.7, $P = .001$) and being a current smoker was associated with a 1.62-fold (95% CI, 1.18–2.13, $P = .002$) greater odds of MetS. Consistent findings were observed when using ATP criteria (odds ratios of 1.37 [95% CI, 1.25–1.45, $P < 10^{-4}$], 1.9 [95% CI, 1.1–3.1, $P = .013$], and 1.68 [95% CI, 1.22–2.27, $P = .001$] for age, illness duration, and smoking status, respectively). Notably, BMI and age at treatment initiation were found to be statistically different across medication groups according to their risk of metabolic side effects. Moreover, an effect of the dose of medication was also observed on the probability to display a MetS (see Supplementary Appendix 1 for more details).


Table 2 shows clinical variables and prevalence of MetS in the subsample of patients aged 35–75 years old (psychiatric sample 2) and in the population-based sample. Notably, the proportion of smokers was twice as high in the psychiatric sample as in the population-based cohort ($P < 10^{-4}$). The psychiatric sample showed generally poorer metabolic health. Indeed, female patients showed a higher prevalence of obesity compared to the population-based sample with both definitions (75.7% vs 55.7% for IDF obesity, $P < 10^{-4}$; and 56.9% vs 32.5% for ATP obesity, $P < 10^{-4}$). Consistent findings were seen in men, but only with the ATP definition (39.9% vs 25.8%, $P = .0006$). For lipid-related traits, psychiatric patients showed greater prevalence of dyslipidemia (HDL hypocholesterolemia prevalence of 33% vs 10.4%, $P < 10^{-4}$; and hypertriglyceridemia prevalence of 35.7% vs 24.9%, $P < .05$). Female patients had a higher prevalence of increased glucose level and diabetes compared to the population-based sample (31.2% vs 26.3%, $P = .0005$; and 8.8% vs 4.0%, $P = .002$, respectively). In contrast, male patients showed a better profile for hypertension prevalence compared to men from the population-based sample (37.5% vs 42.5%, $P = .03$). Men also had a lower hyperglycemia

prevalence (36.9% vs 50.1%, $P < 10^{-4}$), although the difference for diabetes prevalence was not statistically significant (11.0% vs 9.2%, $P = .36$). Significant differences in MetS prevalence were observed between the two cohorts, and this observation was more pronounced in women, for whom the prevalence of cases in the psychiatric sample was nearly twice the prevalence in the population-based sample (31.6% vs 18.0%, $P < 10^{-4}$; and 27.9% vs 15%, $P < 10^{-4}$, according to the IDF and ATP criteria, respectively). This difference was lower for men and significant only according to the ATP definition of MetS (33% vs 26%, $P = .04$).

The comparison between the psychiatric and population-based cohort according to the proportion of participants treated for their metabolic disturbances gave mixed results (see Supplementary Appendix 1 for details).

The estimations of cardiovascular risks with the SCORE and the FRS were similar, showing a very low median risk in both cohorts (Table 3). Of note, men from the population-based sample showed a higher risk of CVD events than men from the psychiatric sample (median [IQR] = 2.54% [1.2%–5.03%] vs 1.72% [0.95%–3.39%], $P < 10^{-4}$). The proportion of participants at high risk of developing a CVD in 10 years (FRS $> 20\%$) for the population-based sample versus the psychiatric sample was 0% versus 0.1% in women and 0.3% versus 1.8% ($P = .01$) in men, while the respective proportions of participants at high risk of dying within 10 years from a CVD event (SCORE $\geq 5\%$) were 8.5% versus 8.4% ($P = .58$) in women and 13.4% versus 16.6% ($P = .42$) in men.

The MetS prevalence, stratified into 2 age groups, is presented in Supplementary Table 4 and in Figure 1. These results highlight that the higher prevalence of MetS in the psychiatric sample was more pronounced among younger adults (aged 35–49 years old). Young female patients were particularly vulnerable, with a MetS prevalence 3 times

Figure 1. Age- and Sex-Stratified Prevalence of Metabolic Syndrome (IDF) and Cardiovascular Disease Medication Intervention in Psychiatric Sample 2 and Comparison With the Population-Based Sample^{a,b,c}

^aMetabolic syndrome defined per the International Disease Federation.

^bStatistical significance for difference between the psychiatric and population-based samples was tested using a weighted statistic according to participants' age (2-sample weighted *t* test). *P* values are Bonferroni-corrected.

^cThe first bar on the left is to be read as follows: in young women with mental disorders, the prevalence of MetS was 26%, and 18% of these women with MetS received a treatment for their metabolic disorder (corresponding to 5% of the young women with mental disorders). The subsequent bars are to be understood similarly.

**P* ≤ .05.

***P* ≤ .005.

****P* ≤ .0005.

Abbreviations: Gpop 35-49 = population-based sample aged 35-49 years, Gpop 50-75 = population-based sample aged 50-75 years, MetS = metabolic syndrome, MetS with treatment = medication intervention among MetS participants (ie, antihypertensive, lipid-lowering, or antidiabetic drug prescription), NS = not significant, Psy 35-49 = psychiatric sample aged 35-49 years, Psy 50-75 = psychiatric sample aged 50-75 years.

higher than that for young women from the population-based sample (25.6% vs 8.0%, $P < 10^{-4}$; and 21.6% vs 6.8%, $P < 10^{-4}$, according to IDF and ATP definitions, respectively). A significant difference was also observed in younger men (32% vs 20.3%, $P = .004$; and 27.2% vs 15.6%, $P = .004$, according to IDF and ATP definitions, respectively). Conversely, in older subjects, the proportion of male patients with MetS was lower than in the population-based sample (38.5% vs 42.8%, $P = .01$; and 35.6% vs 35.2%, $P = .64$, according to IDF and ATP definitions, respectively). The proportion of psychiatric patients with MetS receiving a CVD treatment was similar to that in the population-based participants for all subgroups except for young female patients. Specifically, among younger women with MetS, the proportion of psychiatric patients treated was roughly 2 times less than that of the population-based sample (17.8% vs 38.8%, $P = .0004$; and 21.1% vs 43.7%, $P = .0005$, according to IDF and ATP definitions, respectively).

DISCUSSION

In the present study, cardiovascular risk was estimated using the SCORE and the FRS. We found very low risk in both a large psychiatric Swiss cohort and a control Swiss

population-based cohort. These observations are consistent with previously detected levels of CVD risk in psychiatric populations in Spain, another low-CVD risk European country.²⁷⁻²⁹ The comparison between the two cohorts using both scores did not show statistically significant differences. However, the use of these scores applied to a psychiatric sample might underestimate the risk. Indeed, the calibration of the scores was done with data from the general population, and, as has been extensively shown, cardiovascular events and death rates are higher in the psychiatric population.^{1,30} New equations have been proposed to more accurately evaluate the risk in this vulnerable population such as the PRIMROSE model,³¹ developed specifically for people with severe mental illness, and very recently the QRISK3,³² which considers the presence of several somatic conditions and mental illness in evaluating a patient's risk. However, these models require international validation in well-characterized cohorts and are not yet suitable for clinical applications. Specifically, the need for additional variables such as use of antidepressants or antipsychotics, severe mental illness diagnosis, history of heavy drinking, socioeconomic factors, family history of CVD events, and other comorbidities make those tools more laborious to use.

It is illegal to post this copyrighted PDF on any website.

In the present study, no difference in MetS prevalence was observed across psychiatric diagnoses or between male and female patients, which is in agreement with previous studies.^{33,34} According to our data, the same attention should thus be paid to every psychiatric patient, especially in those taking weight gain-inducing psychotropic drugs, regardless of their sex or diagnosis. It is, however, interesting to note that in the population-based sample, the difference in MetS prevalence between the sexes was striking, especially among younger individuals. This observation is again in line with what is reported in the literature, as mortality rates for CVDs in the general population are higher in males than in females.³⁵ Also, it is reported that biological and social factors for development of cardiovascular diseases differ between the two sexes.³⁶ Factors enabling better cardiovascular health in women (as compared to men) in the general population might be missing in women suffering from severe mental illness. Mental illnesses most likely have greater impact regarding cardiovascular health on women than on men. Thus, although MetS prevalence is similar in both sexes, requiring the same care, more investigation is warranted in female patients to understand the substantial difference between them and women from the general population.

In the present psychiatric sample, about 1 in 4 patients displayed MetS, which is slightly lower than reported in previous meta-analyses^{19,37} showing MetS rates of 32.5% and 37.3% in schizophrenia patients and in bipolar patients respectively. In their meta-analysis, Vancampfort et al³⁷ found that the strongest moderator for MetS rate was the region in which the study took place. The lower prevalence that we report in this study most likely reflects, at least in part, the fact that Switzerland is a low-risk country for CVD.^{15,35} Consistent with previous studies,³⁴ we found that psychiatric patients were more susceptible to metabolic disturbances than subjects from the population-based sample, which may be partially due to the illness and/or exposure to antipsychotic and other psychotropic medication.^{34,37–39} Unfortunately, data on previous psychotropic treatments were not available for psychiatric patients, preventing us from teasing out the weight of the illness from that of the medication. To note, even if the cohort was heterogeneous in terms of illness duration, the psychiatric condition was severe enough in every patient to require the prescription of a psychotropic drug. Besides medication, smoking is a key risk factor for MetS in the psychiatric population. Smoking has previously been demonstrated to be associated with MetS in the general population,⁴⁰ an association further confirmed in the present psychiatric sample. The higher prevalence of smokers in the psychiatric sample (53.9%) as compared to the population-based sample (26.9%) very likely contributes to the difference of MetS observed between the two cohorts. As smoking was also shown to exert an additive risk for CVD events,⁴¹ those patients with MetS who are smokers are at even higher CVD risk.

Notably, older male psychiatric patients presented with a similar or even lower prevalence of MetS than their

counterparts in the population-based sample. Nonetheless, this observation might be biased, as the selection process could have led to inclusion of the healthier patients, with male patients with the worst clinical and/or psychiatric conditions lost to or refusing a clinical follow-up. Those patients were thus quite likely underrepresented in the sample described and used for the present analyses. On the contrary, the proportion of young female patients with MetS was particularly high (25.6%, IDF) as compared to women from the population-based sample (8.0%), and they were far less likely to be treated for metabolic disturbances (17.8% vs 38.8%). Of note, the proportion of young female patients treated for their metabolic disorders was similar to that of young male patients (around 20% for both sex groups). This finding is in contrast to the sex difference on health care-seeking behavior assessed in the general population.⁴²

Age plays a significant role in this sample for CVD treatment prescription, with the proportion of medication intervention being 3 times as large in the older age group as compared to the younger age group. In the RAISE-ETP study conducted by Correll et al,⁹ in first-episode schizophrenia patients with a mean age of 24 years old, only 0.5% of the participants with dyslipidemia received a lipid-lowering treatment. To compare our cohort to the RAISE-ETP study cohort and add evidence for the importance of age in treatment prescription, we selected a subsample from psychiatric sample 1 having the same age distribution as the RAISE-ETP study cohort; when considering those patients (mean = 25 years old, SD = 5, n = 446), a very similar trend was observed, in which only 1.9% of patients with dyslipidemia received a lipid-lowering treatment.

Unfortunately, only CVD drug prescription (ie, antihypertensive, lipid-lowering, or antidiabetic drug prescription) could be assessed, but no information on lifestyle interventions was available. There may have been dietary or physical activity interventions as well as support for smoking cessation or restriction of alcohol intake involved in reaction to metabolic disturbances, especially among the younger age group participants, that could not be accounted for in these analyses. Despite several limitations, it can be assumed that the comparison of the present psychiatric sample with participants from the CoLaus|PsyCoLaus study sheds light on the differences expected between people with mental illness and the general population.

CONCLUSION

The prevalence of MetS was higher in patients with mental illness treated with weight gain-inducing psychotropic drugs than in the general population, especially among young adults. Young female patients seemed to be underdiagnosed and/or undertreated for metabolic traits, and awareness should be raised to detect these cases and give appropriate care. Regular monitoring of metabolic disturbances is of crucial importance in this vulnerable population.

Submitted: February 22, 2019; accepted October 21, 2019.

Published online: March 31, 2020.

Potential conflicts of interest: Dr Eap has received honoraria for conferences or teaching CME courses from Forum für Medizinische Fortbildung, Janssen-Cilag, Lundbeck, Mepha, Otsuka, Sandoz, Servier, Sunovion, Vifor-Pharma, and Zeller in the past 3 years and for writing a review article for the journal *Dialogues in Clinical Neurosciences* (Servier). Dr von Gunten has received honoraria for a conference or workshop participation from Vifor and Schwabe in the previous 3 years. The other authors have no relevant financial or other relationships, and all authors declare no conflict of interest in relation to the content of the article.

Funding/support: This work has been funded in part by the Swiss National Research Foundation (CBE and PC: 320030-120686, 324730-144064, and 320030-173211). Dr Vollenweider received an unrestricted grant from GlaxoSmithKline to build the CoLausPsyCoLaus study. The CoLaus study received financial contributions from GlaxoSmithKline, the Faculty of Biology and Medicine of the University of Lausanne, and the Swiss National Science Foundation (33CSO-122661, 3200BO-111361/2, 3100AO-116323/1, 310000-112552).

Role of the sponsor: The funding sources had no role in the writing of the manuscript or in the decision to submit it for publication.

Acknowledgments: The authors thank M. Gholam-Rezaee, PhD (scientific support; Lausanne University Hospital, Lausanne, Switzerland); C. Brogli and C. Darbellay (logistical assistance; Lausanne University Hospital, Lausanne, Switzerland); E. Retamales (bibliographic help; Lausanne University Hospital, Lausanne, Switzerland); and A. C. Aubert, M. Brocard, N. Cochar, M. Delessert, M. Brawand, S. Jaquet, A. Vullioud, G. Viret (sample analysis; Lausanne University Hospital, Lausanne, Switzerland). None have conflicts of interest to declare. The authors thank the nursing and medical staff who were involved in the metabolic monitoring program.

Supplementary material: Available at PSYCHIATRIST.COM.

REFERENCES

- Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. *JAMA Psychiatry*. 2015;72(4):334–341.
- Atti AR, Ferrari Gozzi B, Zuliani G, et al. A systematic review of metabolic side effects related to the use of antipsychotic drugs in dementia. *Int Psychogeriatr*. 2014;26(1):19–37.
- Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. *Ther Clin Risk Manag*. 2017;13:757–777.
- Leucht S, Cipriani A, Spinelli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. *Lancet*. 2013;382(9896):951–962.
- Abosi O, Lopes S, Schmitz S, et al. Cardiometabolic effects of psychotropic medications. *Horm Mol Biol Clin Invest*. 2018;36(1).
- de Jong M, Belleflamme J, Dale C, et al. Metabolic syndrome in Dutch patients with bipolar disorder: a cross-sectional study. *Prim Care Companion CNS Disord*. 2018;20(6):18m02366.
- Kreyenbuhl J, Medoff DR, Seliger SL, et al. Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes. *Schizophr Res*. 2008;101(1–3):256–265.
- Wysokiński A, Kowman M, Kłoszewska I. The prevalence of metabolic syndrome and Framingham cardiovascular risk scores in adult inpatients taking antipsychotics - a retrospective medical records review. *Psychiatr Danub*. 2012;24(3):314–322.
- Correll CU, Robinson DG, Schooler NR, et al. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. *JAMA Psychiatry*. 2014;71(12):1350–1363.
- Mendis S, Puska P, Norrving B, eds. *Global Atlas on Cardiovascular Disease Prevention and Control*. Geneva, Switzerland: World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization; 2011.
- Pearson TA, Blair SN, Daniels SR, et al; American Heart Association Science Advisory and Coordinating Committee. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. *Circulation*. 2002;106(3):388–391.
- Anderson TJ, Grégoire J, Pearson GJ, et al. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. *Can J Cardiol*. 2016;32(11):1263–1282.
- Redon J. Global cardiovascular risk assessment: strengths and limitations. *High Blood Press Cardiovasc Prev*. 2016;23(2):87–90.
- Conroy RM, Pyörälä K, Fitzgerald AP, et al; SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. *Eur Heart J*. 2003;24(11):987–1003.
- Piepoli MF, Hoes AW, Agewall S, et al; ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Eur Heart J*. 2016;37(29):2315–2381.
- Tunstall-Pedoe H, Kuusamäa K, Mähönen M, et al. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations: monitoring trends and determinants in cardiovascular disease. *Lancet*. 1999;353(9164):1547–1557.
- Marques-Vidal P, Rodondi N, Bochud M, et al. Predictive accuracy of original and recalibrated Framingham risk score in the Swiss population. *Int J Cardiol*. 2009;133(3):346–353.
- Marques-Vidal P, Rodondi N, Bochud M, et al. Predictive accuracy and usefulness of calibration of the ESC SCORE in Switzerland. *Eur J Cardiovasc Prev Rehabil*. 2008;15(4):402–408.
- Mitchell AJ, Vancampfort D, Sweers K, et al. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders: a systematic review and meta-analysis. *Schizophr Bull*. 2013;39(2):306–318.
- Tune JD, Goodwill AG, Sassoon DJ, et al. Cardiovascular consequences of metabolic syndrome. *Transl Res*. 2017;183:57–70.
- Sperling LS, Mechanick JL, Neeland TJ, et al. The CardioMetabolic Health Alliance: working toward a new care model for the metabolic syndrome. *J Am Coll Cardiol*. 2015;66(9):1050–1067.
- Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. *Circulation*. 2003;108(4):414–419.
- Golden SH, Folsom AR, Coresh J, et al. Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study. *Diabetes*. 2002;51(10):3069–3076.
- Alberti KGMM, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. *Lancet*. 2005;366(9491):1059–1062.
- National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation*. 2002;106(25):3143–3421.
- Firmann M, Mayor V, Vidal PM, et al. The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. *BMC Cardiovasc Disord*. 2008;8(1):6.
- Bobes J, Arango C, Aranda P, et al; CLAMORS Study Collaborative Group. Cardiovascular and metabolic risk in outpatients with schizoaffective disorder treated with antipsychotics: results from the CLAMORS study. *Eur Psychiatry*. 2012;27(4):267–274.
- Foguet Boreu Q, Roura Poch P, Bullón Chia A, et al; en representación del grupo de Riesgo Cardiovascular en Trastorno Mental Severo (RISCA-TMS). Cardiovascular risk factors, cardiovascular risk and quality of life in patients with a severe mental disorder. *Aten Primaria*. 2013;45(3):141–148.
- Sanchez-Martinez V, Romero-Rubio D, Abad-Perez MJ, et al. Metabolic syndrome and cardiovascular risk in people treated with long-acting injectable antipsychotics. *Endocr Metab Immune Disord Drug Targets*. 2018;18(4):379–387.
- Khan A, Faucett J, Morrison S, et al. Comparative mortality risk in adult patients with schizophrenia, depression, bipolar disorder, anxiety disorders, and attention-deficit/hyperactivity disorder participating in psychopharmacology clinical trials. *JAMA Psychiatry*. 2013;70(10):1091–1099.
- Osborn DP, Hardoon S, Omar RZ, et al. Cardiovascular risk prediction models for people with severe mental illness: results from the prediction and management of cardiovascular risk in people with severe mental illnesses (PRIMROSE) research program. *JAMA Psychiatry*. 2015;72(2):143–151.
- Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. *BMJ*. 2017;357:j2099.
- Correll CU, Frederickson AM, Kane JM, et al. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. *Bipolar Disord*.

It is illegal to post this copyrighted PDF on any website.

- 2008;10(7):788–797.
34. Vancampfort D, Stubbs B, Mitchell AJ, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. *World Psychiatry*. 2015;14(3):339–347.
 35. Wilkins EWL, Wickramasinghe K, Bhatnagar P, et al. *European Cardiovascular Disease Statistics 2017*. Brussels, Belgium: European Heart Network; 2017.
 36. Woodward M. Rationale and tutorial for analysing and reporting sex differences in cardiovascular associations. *Heart*. 2019;105(22):1701–1708.
 37. Vancampfort D, Vansteelandt K, Correll CU, et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. *Am J Psychiatry*. 2013;170(3):265–274.
 38. Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? *Acta Psychiatr Scand*. 2009;119(3):171–179.
 39. Musil R, Obermeier M, Russ P, et al. Weight gain and antipsychotics: a drug safety review. *Expert Opin Drug Saf*. 2015;14(1):73–96.
 40. Hutcheson R, Rocic P. The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration. *Exp Diabetes Res*. 2012;2012:271028.
 41. Nakatani D, Sakata Y, Sato H, et al; Osaka Acute Coronary Insufficiency Study (OACIS) Group. Clinical impact of metabolic syndrome and its additive effect with smoking on subsequent cardiac events after acute myocardial infarction. *Am J Cardiol*. 2007;99(7):885–889.
 42. Thompson AE, Anisimowicz Y, Miedema B, et al. The influence of gender and other patient characteristics on health care-seeking behaviour: a QUALICOPC study. *BMC Fam Pract*. 2016;17(1):38.

See supplementary material for this article at PSYCHIATRIST.COM.

You are prohibited from making this PDF publicly available.



THE JOURNAL OF CLINICAL PSYCHIATRY

THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY

Supplementary Material

Article Title: Evaluation of Cardiometabolic Risk in a Large Psychiatric Cohort and Comparison With a Population-Based Sample in Switzerland

Author(s): Céline Dubath, PharmD; Aurélie Delacrétaz, PhD; Anaïs Glatard, PhD; Peter Vollenweider, MD; Martin Preisig, MD, MPH; Hélène Richard-Lepouriel, MD; Roland Hasler, PhD; Franziska Gamma, MD, MSc; Alessandra Solida, MD; Jacques Thonney, MD; Sylfa Fassassi, MD; Armin von Gunten, MPhil, MD; Philippe Conus, MD; and Chin B Eap, PhD

DOI Number: <https://doi.org/10.4088/JCP.19m12796>

List of Supplementary Material for the article

1. [Appendix 1](#) Supplementary Methods and Results
2. [Table 1](#) Drugs included in the metabolic follow-up recommendation
3. [Table 2](#) Lipid-lowering, antidiabetic and antihypertensive treatments considered as CVD medication intervention
4. [Table 3](#) Metabolic syndrome criteria
5. [Table 4](#) Prevalence of metabolic syndrome and CVD medication intervention stratified into two age groups in the psychiatric sample 2 and comparison with the population-based sample
6. [Figure 1](#) Flow chart of study participants

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Appendix 1

METHODS

Study design

An institutional guideline of the Department of Psychiatry of the Lausanne University Hospital requires follow-up to assess metabolic parameters when a psychotropic treatment known to induce metabolic side effect is initiated (complete list of medication in **Supplementary Table 1**). Inclusion criteria for the study was the prescription of a psychotropic treatment listed in the institutional guideline for metabolic parameters follow-up. Diagnoses were based on the ICD-10 classification (F20.0-F24.9 and F28-F29: psychotic disorders; F25.0-F25.9; schizoaffective disorders; F30.0-F31.9: bipolar disorders; F32.0-F33.9: depression). Anxiety, personality disorders and mental retardation were classified in “other” disorders.

According to the institutional guideline, monitoring for physical health risk factors was performed at baseline, and one month, three months, and one year after treatment initiation. Body measurements (height, weight, waist circumference, blood pressure) were taken along with blood parameters (total cholesterol (TC), HDL cholesterol (HDL-C), triglycerides (TG) and glucose (GLC)). Presence of CVD treatment medication (i.e. lipid-lowering, antidiabetic and antihypertensive treatments, complete list of medication in **Supplementary Table 2**) was collected. The present study gathered data from the clinical follow-up to run a cross sectional evaluation of the metabolic state of the cohort at the start of a new treatment. Because of the non-interventional post-hoc analysis study design, the Ethic Committee approved the use of clinical data of followed-up patients from 2007 to end of 2015 (PsyClin). From 2015 to 2017, included patients gave written informed consent (PsyMetab). Detailed description of the monitoring and of the cohort study can be found elsewhere¹⁻⁴. Only observations with blood samples drawn in fasting conditions were retained for the present analysis.

For some patients, the clinical monitoring could not be conducted as required and some measures were not carried out. For those, we selected the earliest available observation after treatment initiation. Observations included in the present analysis were thus obtained at baseline for 48% of the sample, month 1 for 21%, month 2 for 3%, month 3 for 19% and month 5 or more for the rest of the sample (9%).

Statistical analyses

The analyses considering illness duration could only be conducted on a subset of patients (n=732, 60% of the cohort), as the information was missing for the other participants. We compared the two extreme quartiles of the cohort, to consider early psychosis versus chronic patients (i.e. patients who experienced 13 years of illness or more versus those with 2 years of illness or less), correcting for age and smoking status.

Prescribed psychotropic treatments were categorized into three groups to test associations with CVD risk scores and MetS according to the expected metabolic side effect.^{5,6} Thus, psychotropic drugs were classified as follow: low risk: haloperidol, pipamperone, flupentixol, asenapine, amisulpride, aripiprazole, lurasidone; medium risk: zuclopenthixol, levomepromazine, paliperidone, risperidone, quetiapine, lithium, mirtazapine; high risk: valproate, olanzapine, clozapine. Since higher dosage is commonly associated with higher metabolic risk, analyses were also run categorizing patients either as taking low or high dose, according to the median prescribed dose of each medication. These analyses were run considering patients measured after the treatment start (n=614).

RESULTS

Psychotropic Medication

Quetiapine represented 31% of all prescriptions, followed by risperidone, olanzapine, aripiprazole, and amisulpride accounting for 15%, 11%, 10% and 8% respectively (data not shown). BMI and age were found to be statistically different across the three medication groups at baseline, with participants being prescribed high versus low risk drugs showing a lower BMI (2 kg/m², 95% CI=0.94-3.7, p=0.001) and being older (7 years older, 95% CI=2-12, p=0.006).

The observation that young patients having a high baseline BMI were more likely to receive a psychotropic medication classified as having a low potential to induce weight gain, suggests that the metabolic secondary effects of drugs seemed to be taken into account in prescription choices. Low risk drugs are thus preferred in young patients but also in patients already presenting an unfavorable metabolic profile. This observation might be specific to this sample's context where awareness has been raised on psychotropic drugs secondary effects for many years. Besides, when considering doses of medication of patients assessed after treatment start, those prescribed a high dose were more susceptible to have MetS using IDF criteria (n=614, OR = 1.5, 95% CI=1.02-2.15, p=0.04). This association was however not statistically significant with ATP definition. (n=614, OR = 1.4, p=0.08).

Cardiovascular Medication

The comparison between the psychiatric and population-based cohort according to the proportion of participants treated for their metabolic disturbances gave mixed results. Specifically, we found a lower rate of antihypertensive drug prescription in psychiatric patients with hypertension as compared to non-psychiatric participants, while patients with dyslipidemia were more often treated with lipid-lowering drugs in the psychiatric sample. No difference was observed in diabetes treatment prescription. Overall, no difference in the prescription of treatment for all risk factors combined was found between the two cohorts among subject diagnosed with MetS.

REFERENCES

1. Choong E, Quteineh L, Cardinaux JR, et al. Influence of CRTC1 polymorphisms on body mass index and fat mass in psychiatric patients and the general adult population. *JAMA psychiatry*. 2013;70(10):1011-1019.
2. Vandenberghe F, Gholam-Rezaee M, Saigi-Morgui N, et al. Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment. *The Journal of clinical psychiatry*. 2015;76(11):e1417-1423.
3. Delacretaz A, Vandenberghe F, Gholam-Rezaee M, et al. Early changes of blood lipid levels during psychotropic drug treatment as predictors of long-term lipid changes and of new onset dyslipidemia. *Journal of clinical lipidology*. 2017.
4. Delacretaz A, Vandenberghe F, Glatard A, et al. Association Between Plasma Caffeine and Other Methylxanthines and Metabolic Parameters in a Psychiatric Population Treated With Psychotropic Drugs Inducing Metabolic Disturbances. *Frontiers in Psychiatry*. 2018;9(573).
5. Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. *World psychiatry : official journal of the World Psychiatric Association (WPA)*. 2015;14(2):119-136.
6. Abosi O, Lopes S, Schmitz S, Fiedorowicz JG. Cardiometabolic effects of psychotropic medications. *Hormone molecular biology and clinical investigation*. 2018.

Supplementary Table 1. Drugs included in the metabolic follow-up recommendation^a

ANTIPSYCHOTICS		ANTIDEPRESSANTS		MOOD STABILIZERS
Atypical (second-generation)	Typical (first-generation)	Tricyclic	Other	
Amisulpride Aripiprazole Asenapine Clozapine Lurasidone Olanzapine Paliperidone Quetiapine Risperidone Sertindole	Chlorprothixene Flupentixol Haloperidol Levomepromazine Pipamperone Promazine Sulpiride Tiapride Zuclopenthixol	Amitriptyline Clomipramine Doxepine Imipramine Nortriptyline Opipramol Trimipramine	Mirtazapine	Carbamazepine Lithium Valproate

^aPsychotropic drugs **in bold** indicate which of the treatments included in the institutional guideline were represented in our study sample.

Supplementary Table 2. Lipid-lowering, antidiabetic and antihypertensive treatments considered as CVD medication intervention

Lipid-lowering drugs	antidiabetic	Antihypertensive		
Atorvastatin Fluvastatin Pravastatin Rosuvastatin Simvastatin Fenofibrate Ezetimibe	Insulin Metformin Pioglitazone Rosiglitazone Glibenclamide Gliclazide Glimepiride Sitagliptine	Enalapril Lisinopril Perindopril Ramipril Trandolapril Candesartan Irbesartan Losartan Olmesartan Telmisartan Valsartan	Amlodipine Diltiazem Felodipine Lercanidipine Nifédipine Verapamil Atenolol Bisoprolol Celiprolol Metoprolol Nebivolol	Propranolol Carvedilol Furosemide Torasemide Amiloride Spironolactone Hydrochlorothiazide Indapamide Aliskirene

Supplementary Table 3. Metabolic syndrome criteria

	Metabolic syndrome (IDF definition)	Metabolic syndrome (NCEP - adapted ATP III)
	A and at least two in B, C, D or E	Three or more of A, B, C, D, or E
A. Central obesity IDF def ATP III def	waist circumference: male ≥ 94 cm, female ≥ 80 cm and/or BMI $> 30\text{kg/m}^2$ waist circumference: male $\geq 102\text{cm}$, female ≥ 88 cm	
B. Triglycerides	≥ 1.7 mmol/l ($\geq 150\text{mg/dl}$) or lipid-lowering treatment	
C. HDL-cholesterol	male ≤ 1.03 mmol/l ($\leq 40\text{mg/dl}$), female ≤ 1.29 mmol/l ($\leq 50\text{mg/dl}$) or lipid-lowering treatment	
D. Blood pressure	$\geq 130/85$ mmHg or treatment for hypertension	
E. Glucose	≥ 5.6 mmol/l ($\geq 100\text{mg/dl}$) or type 2 diabetes treatment	

Supplementary Table 4. Prevalence of metabolic syndrome and CVD medication intervention stratified into two age groups in the psychiatric sample 2 and comparison with the population-based sample


<i>Women</i>	Psy	Gpop	p-val^a
<i>35-49 years old, n</i>	176	1517	
<i>MetS (IDF) prevalence, n(%)</i>	45 (25.6)	121 (8.0)	<10⁻⁴
<i>Treated^b, n(%)</i>	8 (17.8)	47 (38.8)	0.0004
<i>MetS (ATP) prevalence, n(%)</i>	38 (21.6)	103 (6.8)	<10⁻⁴
<i>Treated^b, n(%)</i>	8 (21.1)	45 (43.7)	0.0005
<i>50-75 years old, n</i>	170	2025	
<i>MetS (IDF) prevalence, n(%)</i>	63 (37.1)	512 (25.3)	0.001
<i>Treated^b, n(%)</i>	38 (60.3)	323 (63.1)	0.42
<i>MetS (ATP) prevalence, n(%)</i>	58 (34.1)	421 (20.8)	0.0005
<i>Treated^b, n(%)</i>	36 (62.1)	278 (66.0)	0.35

<i>Men</i>	Psy	Gpop	p-val
<i>35-49 years old, n</i>	147	1511	
<i>MetS (IDF) prevalence, n(%)</i>	47 (32.0)	306 (20.3)	0.004
<i>Treated^b, n(%)</i>	9 (19.1)	67 (21.9)	0.77
<i>MetS(ATP) prevalence, n(%)</i>	40 (27.2)	236 (15.6)	0.004
<i>Treated^b, n(%)</i>	8 (20.0)	54 (22.9)	0.77
<i>50-75 years old, n</i>	135	1675	
<i>MetS (IDF) prevalence, n(%)</i>	52 (38.5)	717 (42.8)	0.01
<i>Treated^b, n(%)</i>	30 (57.7)	405 (56.5)	0.57
<i>MetS(ATP) prevalence, n(%)</i>	48 (35.6)	591 (35.2)	0.64
<i>Treated^b, n(%)</i>	28 (58.3)	359 (60.7)	0.75

^aStatistical significance for difference between the psychiatric and populations based samples was tested using a weighted statistic according to participants' age (two-sample weighted t-test). P-values significant after Bonferroni correction are in bold (≤ 0.025)

^bTreated: prevalence of any CVD medication intervention among MetS participants (i.e. antihypertensive, lipid lowering or antidiabetic drug prescription)

Abbreviations: Gpop= population-based sample; MetS= metabolic syndrome ; psy= psychiatric sample



Supplementary Figure 1. Flow chart of study participants